Profile data is unavailable for this security.
About the company
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
- Revenue in USD (TTM)80.00k
- Net income in USD-37.51m
- Incorporated2005
- Employees24.00
- LocationAthersys Inc3201 Carnegie AveCLEVELAND 44115-2634United StatesUSA
- Phone+1 (216) 431-9900
- Fax+1 (216) 361-9495
- Websitehttps://www.athersys.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Himalaya Technologies Inc | 0.00 | -629.85k | 182.98k | 2.00 | -- | -- | -- | -- | -0.003 | -0.003 | 0.00 | -0.002 | 0.00 | -- | -- | -- | -270.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -193.23 | -- | -- | -- |
| Gelstat Corp | 1.68m | -1.22m | 183.75k | 2.00 | -- | 0.0251 | -- | 0.1093 | -0.0033 | -0.0033 | 0.0046 | 0.014 | 0.3021 | 4.17 | -- | 840,285.00 | -21.96 | -- | -26.29 | -- | 28.99 | -- | -72.69 | -- | 0.3216 | -134.79 | 0.0267 | -- | -66.81 | -- | -60.17 | -- | -- | -- |
| Nxgen Brands Inc | -100.00bn | -100.00bn | 213.78k | -- | -- | -- | -- | -- | -- | -- | -- | -0.0195 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0681 | -- | -- | -- | -62.57 | -- | 80.39 | -- | -- | -- |
| Ampio Pharmaceuticals Inc | 0.00 | -8.63m | 249.78k | 6.00 | -- | 0.0546 | -- | -- | -11.10 | -11.10 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -89.34 | -72.16 | -109.57 | -84.33 | -- | -- | -- | -- | 2.32 | -- | 0.00 | -- | -- | -- | 47.16 | -- | -- | -- |
| Limitless Venture Group Inc | 0.00 | -10.68m | 255.10k | -- | -- | -- | -- | -- | -117.82 | -117.82 | 0.00 | -9.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -37.95 | -- | -- | -- | -- | -- | -- | -- | -- |
| Bioquest Corp | 0.00 | -507.41k | 260.72k | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Athersys Inc | 80.00k | -37.51m | 277.73k | 24.00 | -- | -- | -- | 3.47 | -2.03 | -2.03 | 0.004 | -1.36 | 0.0037 | -- | 0.2424 | 3,333.33 | -174.57 | -120.93 | -- | -206.72 | -- | -- | -46,883.75 | -727.72 | -- | -- | -- | -- | -3.43 | 7.51 | 16.58 | -- | 6.85 | -- |
| DMK Pharmaceuticals Corp | 3.62m | -21.16m | 292.96k | 11.00 | -- | -- | -- | 0.0809 | -8.69 | -9.18 | 1.04 | -0.4918 | 0.3432 | 5.66 | 5.54 | 329,062.70 | -200.59 | -79.00 | -- | -113.05 | -37.30 | 4.85 | -584.50 | -347.59 | 0.5355 | -- | -- | -- | 115.34 | -18.31 | 24.28 | -- | -20.10 | -- |
| Baudax Bio Inc | 310.00k | -25.83m | 309.51k | 9.00 | -- | -- | -- | 0.9984 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
| CNBX Pharmaceuticals Inc | 540.25k | -1.23m | 332.89k | 2.00 | -- | -- | -- | 0.6162 | -0.0583 | -0.0583 | 0.0237 | -0.0758 | 1.73 | -- | -- | 270,125.00 | -393.70 | -73.32 | -- | -99.80 | 6.37 | -- | -228.08 | -3,970.88 | -- | -1.37 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Respirerx Pharmaceuticals Inc | 0.00 | -2.17m | 350.80k | 2.00 | -- | -- | -- | -- | -0.014 | -0.014 | 0.00 | -0.0412 | 0.00 | -- | -- | 0.00 | -2,255.78 | -2,491.69 | -- | -- | -- | -- | -- | -- | -- | -2.90 | -- | -- | -- | -- | -12.78 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Strategic Wealth Designers LLCas of 31 Dec 2023 | 274.74k | 0.45% |
| CIBC Asset Management, Inc.as of 30 Jun 2023 | 36.38k | 0.06% |
| BBVA Asset Management SA SGIICas of 31 Dec 2023 | 16.02k | 0.03% |
| State of Wisconsin Investment Boardas of 31 Dec 2017 | 2.50k | 0.00% |
| FSC Securities Corp.as of 30 Sep 2023 | 460.00 | 0.00% |
| Ancora Family Wealth Advisors LLCas of 31 Dec 2023 | 310.00 | 0.00% |
| Arlington Partners LLCas of 31 Mar 2024 | 250.00 | 0.00% |
| Game Plan Financial Advisors LLCas of 31 Mar 2024 | 120.00 | 0.00% |
| Asset Dedication LLCas of 31 Mar 2024 | 49.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 31 Dec 2023 | 0.00 | 0.00% |
